Suraksha Diagnostic Limited — PPTs, 29-05-2025: Investor Presentation

1. **Financial Highlights:**

Suraksha Diagnostic Limited’s consolidated revenue rose 15% YoY to ₹2559.39 million for FY25. EBITDA grew 16% to ₹850.88 million, maintaining a steady margin near 33.8%. PAT surged 34% to ₹309.78 million, with a PAT margin of 12.3%. Q4 revenue was up 17% YoY at ₹659.12 million; EBITDA fell slightly by 2% QoQ to ₹200.05 million with a 30.7% margin, while PAT increased 13% YoY to ₹71.7 million. The balance sheet shows an increase in property, plant & equipment to ₹1471.37 million and equity at ₹2112.4 million. Net cash position is evident with net debt/equity at -0.33.

2. **Strategic Initiatives & Growth Drivers:**

Acquisition of 63% in Fetomat Wellness Pvt Ltd enhances presence in fetal and maternal diagnostics. Expansion plans involve scaling diagnostic centres through a hub-and-spoke model, boosting lab capacity, and growing home collection and medical consultation offerings. Investments in digital technology aim to improve customer experience and efficiency. Regional expansion focuses on Eastern and North-Eastern India with a goal to consolidate leadership and enter new adjacent markets.

3. **Business Developments:**

Fetomat acquisition broadens Suraksha’s fetal medicine portfolio and integrated diagnostics capabilities. The company operates 55 diagnostic centres and 9 labs (including 4 NABL accredited), offering over 2,300 tests. It supports 171 collection centres and omnichannel services like online bookings and digital reports to deepen customer engagement.

4. **Market Position & Competitive Advantage:**

Suraksha leads as the largest integrated diagnostic chain in Eastern India, leveraging scale and a strong network. Its “polyclinic” model combining pathology, radiology, and consultation services creates high entry barriers. The hub-and-spoke structure drives scale efficiencies and strong brand presence in a fragmented market, allowing premium pricing. Advanced clinical infrastructure and experienced leadership strengthen its competitive moat.

5. **Investor Implications:**

Robust financials, strategic acquisitions, and focused regional growth underscore positive growth potential. Integration of advanced fetal diagnostic services and digital initiatives support sustainable margin improvement. Execution risk exists around geographical expansion and acquisitions, but the company’s dominant presence and scalable model suggest meaningful value creation ahead.